Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-14833 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- N-Ras Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with porcine based on sequence homology.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L, West C, Hoff DV, Dent P
Frontiers in oncology 2020;10:1331
Frontiers in oncology 2020;10:1331
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis using a NRAS polyclonal antibody (Product # PA5-14833) in MCF-7 cell lysates (35 µg per lane).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of NCI-H460 cells using a NRAS polyclonal antibody (Product # PA5-14833) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 GZ17-6.02 and doxorubicin interact after a 3 h exposure to activate an ATM-AMPK-ULK1- autophagy pathway concomitant with inactivation of mTOR and increased Beclin1 expression. HT1080 human sarcoma cells were treated with vehicle control, GZ17-6.02 (2 muM final curcumin), doxorubicin (200 nM) or the drugs in combination for 3 and 6 h. Cells were fixed in place and immunostained to detect the total expression and the total phosphorylation of the indicated proteins. The phosphorylation of each phosphoprotein was corrected for total protein expression; non-phosphoproteins had their expression corrected using invariant ERK2 expression. ( n = 3 +/-SD) * p < 0.05 less than vehicle control; # p < 0.05 greater than vehicle control.
